BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

This study has been terminated.
Sponsor:
Collaborators:
Cancer International Research Group
Hoffmann-La Roche
Genentech, Inc.
Information provided by (Responsible Party):
NSABP Foundation Inc
ClinicalTrials.gov Identifier:
NCT00625898
First received: February 21, 2008
Last updated: July 7, 2014
Last verified: July 2014
  Purpose

The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.


Condition Intervention Phase
Breast Cancer
Drug: Docetaxel
Drug: Trastuzumab
Drug: Carboplatin
Drug: Bevacizumab
Drug: 5-Fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients With HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab With Chemotherapy Plus Trastuzumab Plus Bevacizumab

Resource links provided by NLM:


Further study details as provided by NSABP Foundation Inc:

Primary Outcome Measures:
  • Invasive Disease-free Survival (IDFS) [ Time Frame: up to 10 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Invasive disease-free survival (IDFS) within chemotherapy cohorts [ Time Frame: up to 10 years ] [ Designated as safety issue: No ]
  • Disease-free survival (DFS) [ Time Frame: up to 10 years ] [ Designated as safety issue: No ]
  • Overall survival (OS) [ Time Frame: Time from randomization until death from any cause or up to a maximum of 10 years from study entry ] [ Designated as safety issue: No ]
  • Recurrence-free interval (RFI) [ Time Frame: Time from randomization until local, regional or distant recurrence or up to a maximum of 10 years from study entry ] [ Designated as safety issue: No ]
  • Distant recurrence-free interval (DRFI) [ Time Frame: Time from randomization until distant disease recurrence only or up to a maximum of 10 years from study entry ] [ Designated as safety issue: No ]
  • Cardiac toxicity. Cumulative incidence of severe cardiac events defined as definite or probable cardiac death, or NYHA Class III or IV CHF [ Time Frame: 2-3 weeks after cycle 3; 2-3 weeks after last chemotherapy dose; 7, 10, 18, 36, and 60 months from randomization ] [ Designated as safety issue: Yes ]
  • Non-cardiac toxicity. Frequencies of adverse events categorized using the NCI CTCAE v3.0. [ Time Frame: within 3 days of each chemotherapy cycle; 2-3 weeks following last chemotherapy dose; every 6 weeks during targeted therapy; every 6 months through year 5; every 12 months years 6 - 10 ] [ Designated as safety issue: Yes ]
  • Identification of biomarkers (from tumor and serum/plasma) predictive for the level of benefit from the addition of bevacizumab to standard adjuvant systemic treatment for HER2-positive breast cancer as well as for cardiac toxicity [ Time Frame: baseline, during therapy and follow-up, within 2 weeks of LVEF assessments, any protocol-specified cardiac event, and after diagnosis of recurrence ] [ Designated as safety issue: No ]

Enrollment: 3509
Study Start Date: April 2008
Study Completion Date: July 2014
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1A: TCH-H
Docetaxel (T), Carboplatin (C), and Trastuzumab (H) followed by Trastuzumab (H)
Drug: Docetaxel

75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B

100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

Other Name: Taxotere
Drug: Trastuzumab

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

Other Name: Herceptin
Drug: Carboplatin
6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
Experimental: 1B: TCHB-HB
Docetaxel (T), Carboplatin (C), Trastuzumab (H), Bevacizumab (B) followed by Trastuzumab (T) and Bevacizumab (B)
Drug: Docetaxel

75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B

100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

Other Name: Taxotere
Drug: Trastuzumab

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

Other Name: Herceptin
Drug: Carboplatin
6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
Drug: Bevacizumab

15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B

15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B

Other Name: Avastin
Active Comparator: 2A: TH-FEC-H
Docetaxel (T) and Trastuzumab (H) followed by 5-fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H)
Drug: Docetaxel

75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B

100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

Other Name: Taxotere
Drug: Trastuzumab

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

Other Name: Herceptin
Drug: 5-Fluorouracil
600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Drug: Epirubicin
90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Drug: Cyclophosphamide
600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Experimental: 2B: THB-FEC-HB
Docetaxel (T), Trastuzumab (H), and Bevacizumab (B) followed by 5-Fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H) and Bevacizumab (B)
Drug: Docetaxel

75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B

100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B

Other Name: Taxotere
Drug: Trastuzumab

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B

First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B

Other Name: Herceptin
Drug: Bevacizumab

15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B

15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B

Other Name: Avastin
Drug: 5-Fluorouracil
600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Drug: Epirubicin
90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
Drug: Cyclophosphamide
600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6

Detailed Description:

This Phase III, randomized, open-label trial will determine whether the regimens of chemotherapy plus trastuzumab plus bevacizumab improve invasive disease-free survival (IDFS) relative to the regimens of chemotherapy plus trastuzumab. Secondary aims include determining whether the addition of bevacizumab to chemotherapy plus trastuzumab will improve disease-free survival (DFS), overall survival (OS), recurrence-free interval (RFI), and distant recurrence-free interval (DRFI). The benefit of adding bevacizumab for IDFS, DFS, OS, RFI, and DRFI will also be evaluated for each of the two chemotherapy regimens. The cardiac and non-cardiac toxicities of each of the regimens will also be evaluated.

Following local determination that the tumor is HER2-positive for gene amplification by in situ hybridization or is IHC 2+ or 3+, a tumor sample must be submitted for HER2 testing by a designated central laboratory. If central testing confirms that the tumor is HER2-positive (either positive by FISH or IHC 3+) and all other eligibility criteria have been met, the patient will be randomized to a regimen of chemotherapy and trastuzumab with or without bevacizumab.

Patients in the trial will be enrolled in one of two chemotherapy regimen cohorts. One cohort will receive 6 cycles of docetaxel/carboplatin plus trastuzumab (TCH) with or without bevacizumab; the other cohort will receive 3 cycles of docetaxel plus trastuzumab given with or without bevacizumab followed by 3 cycles of 5-Fluorouracil, Epirubicin, Cyclophosphamide (TH-FEC). With both regimens, patients will continue trastuzumab with or without bevacizumab following chemotherapy to complete 1 year of targeted therapy. Following completion of chemotherapy, patients will also receive adjuvant radiotherapy and endocrine therapy as clinically indicated.

The trial will be conducted by investigators affiliated with the Cancer International Research Group (CIRG) and the National Surgical Adjuvant Breast and Bowel Project (NSABP). CIRG and NSABP investigators will only enroll patients in the TCH regimen cohort. Additional investigators, referred to in the protocol as Independent Investigators, will enroll patients in both the TCH regimen or the TH-FEC regimen cohort depending on institutional preference for the one regimen that will be used by that institution for the duration of the trial.

Patients will be given the option of allowing their tumor samples to be used for the BETH translational research and correlative science studies. Also, patients will be asked to consent to the submission of blood and serum samples at scheduled time points during the study.

LVEF assessments will be performed before study entry and then at scheduled time points during therapy and at 18, 36, and 60 months following randomization.

The planned sample size for the trial is 3,000 patients randomized in the faster accruing cohort and a minimum of 3,500 patients overall.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Life expectancy of at least 10 years, excluding their diagnosis of breast cancer.
  • Women who have had breast reconstruction utilizing tissue expanders must be in agreement with delaying surgery to replace the tissue expanders with permanent implants until 3 months following the last dose of bevacizumab
  • Women of reproductive potential must agree to use an effective non-hormonal method of contraception (for example condoms, some intrauterine devices, diaphragms, vasectomized partner, or abstinence) during therapy and for at least 6 months after the last dose of bevacizumab and/or trastuzumab.
  • Submission of tumor samples from the breast surgery for central HER2 testing is required for all patients prior to enrollment in the BETH Trial
  • Signed and dated IRB/EC-approved consent
  • ECOG performance status of 0 or 1
  • The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination.
  • The breast cancer must be HER2-positive based on test results as follows: Local testing (if available) should demonstrate that the tumor is IHC 2+ or 3+ or is considered to be HER2-positive for gene amplification by FISH, CISH, or other in situ hybridization (ISH) method. If local ISH test results are considered equivocal, the tumor can be submitted for central HER2 testing. (If local testing is not possible, the tumor can be submitted for central HER2 testing.) Central testing (a requirement for ALL patients) must demonstrate that the tumor is HER2-positive which is defined as FISH-positive and/or IHC 3+.
  • All of the following staging criteria (according to the 6th edition of the AJCC Cancer Staging Manual) must be met: By pathologic evaluation, primary tumor must be pT1-3; By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b. If pN0, at least one of the following criteria must be met: Pathologic tumor size > 2.0 cm; ER negative and PgR negative; Histologic and/or nuclear grade 2 (intermediate) or 3 (high); or Age < 35 years
  • Patients must have undergone either a total mastectomy or breast conserving surgery (lumpectomy).
  • For patients who undergo lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional operative procedures may be performed to obtain clear margins. If tumor is still present at the resected margin after re-excision(s), the patient must undergo total mastectomy to be eligible. (Patients with margins positive for lobular carcinoma in situ [LCIS] are eligible without additional resection.)
  • For patients who undergo mastectomy, margins must be free of gross residual tumor. Patients with microscopic positive margins are eligible.
  • Patients must have completed one of the following procedures for evaluation of pathologic nodal status: Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph nodes if the sentinel node (SN) is positive; Sentinel lymphadenectomy alone if pathologic nodal staging based on sentinel lymphadenectomy is pN0, pN1mi or pN1b; or Axillary lymphadenectomy without SN isolation procedure.
  • The interval between the last surgery for breast cancer (treatment or staging) and randomization must be at least 28 days but no more than 84 days.
  • Patients must have ER analysis performed on the primary tumor prior to randomization. If ER analysis is negative, then PgR analysis must also be performed.
  • The most recent postoperative blood counts, performed within 6 weeks prior to randomization, must meet the following criteria: ANC must be greater than or equal to 1200/mm3; Platelet count must be greater than or equal to 100,000/mm3; and Hemoglobin must be greater than or equal to 10 g/dL.
  • The following criteria for evidence of adequate hepatic function must be met based on the results of the most recent postoperative tests performed within 6 weeks prior to randomization: total bilirubin must be less than or equal to upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and alkaline phosphatase must be less than or equal to 2.5 x ULN for the lab; and AST must be less than or equal to 1.5 x ULN for the lab. Alkaline phosphatase and AST may not both be > the ULN.
  • Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the study if liver imaging (CT, MRI, PET scan, or PET-CT scan performed within 3 months prior to randomization) does not demonstrate metastatic disease and the requirements for evidence of adequate hepatic function are met.
  • Patients with alkaline phosphatase that is > ULN but less than or equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan,PET scan, or PET-CT scan (performed within 3 months prior to randomization) does not demonstrate metastatic disease.
  • The following criteria for renal function must be met based on the results of the most recent postoperative tests performed within 6 weeks prior to randomization: Serum creatinine must be less than or equal to ULN for the lab. Measured or calculated creatinine clearance must be > 60 mL/min.
  • A urine sample must be tested for protein by determination of the urine protein/creatinine (UPC) ratio or by urine dipstick. UPC ratio must be less than 1.0. Urine dipstick must indicate 0-1+ protein. If dipstick reading is greater than or equal to 2+, determine the UPC ratio, which must be less than 1.0, or collect a 24-hour urine specimen, which must demonstrate < 1.0 g of protein per 24 hours.
  • LVEF assessment must be performed within 3 months prior to randomization. The LVEF must be greater than or equal to 55% regardless of the cardiac imaging facility's lower limit of normal (LLN).
  • The ECG (performed within 3 months prior to randomization) must not have demonstrated any of the following conditions: ventricular arrhythmias except for benign premature ventricular contractions; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; and conduction abnormality requiring a pacemaker.

Exclusion Criteria:

  • Inflammatory breast cancer.
  • Definitive clinical or radiologic evidence of metastatic disease. (Chest imaging [mandatory for all patients] and other imaging [if required] must have been performed within 3 months prior to randomization.)
  • Synchronous or previous contralateral invasive breast cancer (Patients with synchronous or previous contralateral DCIS or LCIS are eligible).
  • History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral DCIS treated with excision and RT. (Patients with history of ipsilateral LCIS are eligible.)
  • History of non-breast malignancies within the 5 years prior to study entry, except for the following: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin.
  • Previous therapy with anthracyclines, taxanes, carboplatin, trastuzumab, or bevacizumab for any malignancy.
  • RT, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to randomization.
  • Continued therapy with any hormonal agent such as raloxifene or tamoxifen (or other SERM) or an aromatase inhibitor. (Patients are eligible if these medications are discontinued prior to randomization.)
  • Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy, etc. Patients are eligible if these medications are discontinued prior to randomization.
  • Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens. This includes but is not confined to: Active cardiac disease - angina pectoris that requires the use of anti-anginal medication; ventricular arrhythmias except for benign premature ventricular contractions; supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; conduction abnormality requiring a pacemaker; valvular disease with documented compromise in cardiac function; and symptomatic pericarditis. History of cardiac disease - myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function; history of documented CHF; and documented cardiomyopathy.
  • Uncontrolled hypertension defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg, with or without anti-hypertensive medication. (BP must be assessed within 28 days prior to randomization.) Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria.
  • History of hypertensive crisis or hypertensive encephalopathy.
  • History of TIA or CVA.
  • History of any arterial thrombotic event within 12 months before randomization.
  • Symptomatic peripheral vascular disease.
  • Intrinsic lung disease resulting in dyspnea.
  • Unstable diabetes mellitus.
  • Active infection or chronic infection requiring chronic suppressive antibiotics.
  • Any significant bleeding within 6 months before randomization, exclusive of menorrhagia in premenopausal women.
  • Non-healing wound, skin ulcers, or incompletely healed bone fracture.
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to planned start of study therapy.
  • Anticipation of need for major surgical procedures during study therapy and for at least 3 months following completion of bevacizumab.
  • Gastroduodenal ulcer(s) documented by endoscopy to be active within 6 months before randomization.
  • History of GI perforation, abdominal fistulae, or intra-abdominal abscess.
  • Known bleeding diathesis or coagulopathy.
  • Requirement for therapeutic doses of coumadin or equivalent.
  • Sensory/motor neuropathy greater than or equal to grade 2, as defined by the NCI CTCAE v3.0.
  • Conditions that would prohibit administration of corticosteroids.
  • Chronic daily treatment with corticosteroids (dose of > 10 mg/day methylprednisolone equivalent) (excluding inhaled steroids).
  • History of hypersensitivity reaction to drugs formulated with polysorbate 80.
  • Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be performed within 14 days prior to randomization according to institutional standards for women of child-bearing potential.)
  • Other non-malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up.
  • Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.
  • Use of any investigational product within 4 weeks prior to enrollment in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00625898

  Hide Study Locations
Locations
United States, Alabama
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Clearview Cancer Institute-Decatur
Decatur, Alabama, United States, 35601
Clearview Cancer Institute- Huntsville
Huntsville, Alabama, United States, 35805
Clearview Cancer Institute
Huntsville, Alabama, United States, 35801
United States, Arizona
Northern Arizona Hematology & Onclogy Associates
Flagstaff, Arizona, United States, 86001
Northern Arizona Hematology & Oncology Associates
Sedona, Arizona, United States, 86336
United States, California
Central Hematology/Oncology Medical Group, Inc.
Alhambra, California, United States, 91801
Comprehensive Blood and Cancer Center
Bakersfield, California, United States, 93309
Kaiser Permanente-Baldwin Park
Baldwin Park, California, United States, 91706
Kaiser Permanente-Bellflower
Bellflower, California, United States, 90706
Providence Saint Joseph Medical Center
Burbank, California, United States, 91505
Scripps Clinic Encinitas
Encinitas, California, United States, 92024
Hematology-Encinitas
Encinitas, California, United States, 92024
Kaiser Permanente-Fontana
Fontana, California, United States, 92335
St. Jude Heritage Healthcare
Fullerton, California, United States, 92835
Breastlink Medical Group, Inc
Hawthorne, California, United States, 90250
Pacific Shores Medical Group
Huntington Beach, California, United States, 92648
Kaiser Permanente-Irvine
Irvine, California, United States, 92618
Sabina R. Wallach, MD., AMC
La Jolla, California, United States, 92037
Scripps Cancer Center-San Diego
La Jolla, California, United States, 92037
Hematology-La Jolla
La Jolla, California, United States, 92037
Antelope Valley Cancer Center
Lancaster, California, United States, 93534
Kaiser Permanente-West Los Angeles
Los Angeles, California, United States, 90034
Kaiser Permanente-Sunset
Los Angeles, California, United States, 90027
Kaiser Permanente-Oakland
Oakland, California, United States, 94611
North County Oncology Medical Clinic, Inc.
Oceanside, California, United States, 92056
Kaiser Permanente-Orange County
Panorama City, California, United States, 92807
Kaiser Permanente-Panorama City
Panorama City, California, United States, 91042
Wilshire Oncology Medical Group
Pasadena, California, United States, 91750
Cancer Care Associates Medical Group, Inc.
Redondo Beach, California, United States, 90277
Kaiser Permanente-Riverside
Riverside, California, United States, 92505
Sutter Roseville Medical Center
Roseville, California, United States, 95661
Kaiser Permanente-Roseville
Roseville, California, United States, 95661
Kaiser Permanente-Sacramento
Roseville, California, United States, 95825
Sutter Medical Group
Sacramento, California, United States, 95816
Sutter Medical Center
Sacramento, California, United States, 95816
Scripps Clinic-Rancho Bernardo
San Diego, California, United States, 92128
Kaiser Permanente-San Diego
San Diego, California, United States, 92120
Sharp Rees-Stealy
San Diego, California, United States, 92123
Peter T. Reissman, MD, Inc
San Diego, California, United States, 92103
William Stanton, MD, Inc
San Diego, California, United States, 92103
Kaiser Permanente-San Francisco
San Francisco, California, United States, 94115
Kaiser Permanente-Hayward
San Francisco, California, United States, 94545
Santa Barbara Hematology Oncology Medical Group
Santa Barbara, California, United States, 93105
Sansum Clinic
Santa Barbara, California, United States, 93105
Kaiser Permanente-Santa Clara
Santa Clara, California, United States, 95051
Central Coast Medical Oncology Corporation
Santa Maria, California, United States, 93454
Kaiser Permanente-South San Francisco
South San Francisco, California, United States, 94080
Stanford University Medical Center
Stanford, California, United States, 94305
UCLA/Santa Clarita Valley Cancer Center
Valencia, California, United States, 91355
Kaiser Permanente-Vallejo
Vallejo, California, United States, 94589
San Diego Pacific Oncology & Hematology-Vista
Vista, California, United States, 92803
Kaiser Permanente-Walnut Creek
Walnut Creek, California, United States, 94596
Kaiser Permanente-Woodland Hills
Woodland Hills, California, United States, 91367
United States, Colorado
University of Colorado Cancer Center
Aurora, Colorado, United States, 80045
Penrose Cancer Center
Colorado Springs, Colorado, United States, 80907
Cypress Hematology/Oncology
Denver, Colorado, United States, 80210
CCOP-Colorado Cancer Research Prog. Inc.(Administrative Only)
Denver, Colorado, United States, 80224
Kaiser Permanente-Franklin
Denver, Colorado, United States, 80205
Rocky Mountain Cancer Center - Midtown
Denver, Colorado, United States, 80218
Shaw Regional Cancer Center
Edwards, Colorado, United States, 81632
North Colorado Medical Center
Greeley, Colorado, United States, 80631
Kaiser Permanente Rock Creek
Lafayette, Colorado, United States, 80026
McKee Medical Center
Loveland, Colorado, United States, 80538
Exempla Lutheran Medical Center
Wheat Ridge, Colorado, United States, 80033
United States, Connecticut
Oncology Associates P.C.-Avon
Avon, Connecticut, United States, 06001
Bridgeport Hospital
Bridgeport, Connecticut, United States, 06610
Medical Specialists of SWIM
Bridgeport, Connecticut, United States, 06606
Oncology Associates of Bridgeport-Fairfield
Fairfield, Connecticut, United States, 06824
Medical Specialists of Fairfield
Fairfield, Connecticut, United States, 06824
Hartford Hospital
Hartford, Connecticut, United States, 06102
Oncology Associates P.C.-Hartford
Hartford, Connecticut, United States, 06106
Connecticut Multi Specialty Group-Hartford
Hartford, Connecticut, United States, 06106
Medical Oncology and Hematology, P.C.
Meriden, Connecticut, United States, 06451
Eastern Connecticut Hematology & Oncology Associates
Norwich, Connecticut, United States, 06360
Black Rock Medical Group
Trumbull, Connecticut, United States, 06611
Oncology Associates of Bridgeport-Trumbull
Trumbull, Connecticut, United States, 06611
Medical Oncology & Hematology, P.C.
Waterbury, Connecticut, United States, 06708
Connecticut Multi Specialty Group-Wethersfield
Wethersfield, Connecticut, United States, 06109
Oncology Associates P.C.-Willimantic
Willimantic, Connecticut, United States, 06226
United States, Delaware
CCOP, Christiana Care Health Services Inc.
Newark, Delaware, United States, 19718
United States, District of Columbia
Washington Cancer Institute
Washington, District of Columbia, United States, 20010
Washington Oncology-Hematology Center, PC-Washington
Washington, District of Columbia, United States, 20037
Sibley Memorial Hospital
Washington, District of Columbia, United States, 20016
United States, Florida
Lynn Cancer Institute
Boca Raton, Florida, United States, 33428
Florida Cancer Specialists-Bonita Springs
Bonita Springs, Florida, United States, 34135
Florida Cancer Specialists-Bradenton
Bradenton, Florida, United States, 34209
Florida Cancer Specialists, Brandon
Brandon, Florida, United States, 33511
Florida Cancer Specialists-Cape Coral Parkway
Cape Coral, Florida, United States, 33914
Florida Cancer Specialists-Cape Coral Del Prado
Cape Coral, Florida, United States, 33990
Florida Cancer Specialists
Clearwater, Florida, United States, 33756
Florida Cancer Specialists-Englewood
Englewood, Florida, United States, 34223
Florida Cancer Specialists-Fort Myers Broadway
Ft. Myers, Florida, United States, 33901
Florida Cancer Specialists-Fort Myers Summerlin
Ft. Myers, Florida, United States, 33908
Robert R. Carroll, MD, PA
Gainesville, Florida, United States, 32605
Integrated Community Oncology Network
Jacksonville, Florida, United States, 32258
Lakeland Regional Cancer Center
Lakeland, Florida, United States, 33805
Florida Cancer Specialists-NAPA Ridge
Naples, Florida, United States, 34119
Florida Cancer Specialists-Naples Goodlette
Naples, Florida, United States, 34102
Integrated Community Oncology Network
Orange Park, Florida, United States, 32073
Florida Hospital Cancer Institute
Orlando, Florida, United States, 32804
Florida Cancer Specialists, Cornerstone
Palm Harbor, Florida, United States, 34684
Florida Cancer Specialists-Port Charlotte
Port Charlotte, Florida, United States, 33980
Florida Cancer Specialists-Downtown
Sarasota, Florida, United States, 34236
Florida Cancer Specialist-Cattleman
Sarasota, Florida, United States, 34232
Florida Cancer Specialists-Park Place
St. Petersburg, Florida, United States, 33756
Florida Cancer Specialists
Tampa, Florida, United States, 33614
Florida Cancer Specialists
Tampa, Florida, United States, 33603
Florida Cancer Specialists-Venice
Venice, Florida, United States, 34292
Florida Cancer Specialists-Venice Island
Venice, Florida, United States, 34285
Palm Beach Cancer Institute
West Palm Beach, Florida, United States, 33401
United States, Georgia
Phoebe Putney Memorial Hospital
Albany, Georgia, United States, 31701
Northeast Georgia Cancer Care, LLC
Athens, Georgia, United States, 30607
Grady Healthsystem
Atlanta, Georgia, United States, 30303
Emory University
Atlanta, Georgia, United States, 30322
Augusta Oncology Associates
Augusta, Georgia, United States, 30901
Northwest Georgia Oncology Centers PC
Austell, Georgia, United States, 30106
Northwest Georgia Oncology Centers PC
Carrollton, Georgia, United States, 30117
Northwest Georgia Oncology Centers PC
Cartersville, Georgia, United States, 30121
Suburban Hematology-Oncology Associates
Lawrenceville, Georgia, United States, 30045
Georgia Cancer Specialists
Macon, Georgia, United States, 31217
Central Georgia Cancer Care
Macon, Georgia, United States, 31201
Georgia Cancer Specialists
Marietta, Georgia, United States, 30060
Suburban Hematology Oncology Associates PC
Snellville, Georgia, United States, 30078
United States, Hawaii
Straub Clinic and Hospital
Honolulu, Hawaii, United States, 96813
Oncare Hawaii, Inc-KMP
Honolulu, Hawaii, United States, 96817
Oncare Hawaii, Inc-POB2
Honolulu, Hawaii, United States, 96813
University of Hawaii
Honolulu, Hawaii, United States, 96813
United States, Idaho
Kootenai Cancer Center
Coeur D'Alene, Idaho, United States, 83814
Mountain States Tumor Institute
Meridian, Idaho, United States, 83642
Mountain States Tumor Institute
Twin Falls, Idaho, United States, 83301
United States, Illinois
Cancer Care & Hematology Specialists of Chicagoland
Arlington, Illinois, United States, 60005
Rush University Medical Center
Chicago, Illinois, United States, 60612
MBCCOP, John H. Stroger, JR., Hospital of Cook County-Chicago
Chicago, Illinois, United States, 60612
Crossroads Cancer Center
Decatur, Illinois, United States, 62401
Cancer Care Specialists-Central Illinois
Decatur, Illinois, United States, 62526
Decatur Memorial Hospital
Decatur, Illinois, United States, 62526
Edward Hospital
Naperville, Illinois, United States, 60540
Edward Cancer Center Plainfield
Plainfield, Illinois, United States, 60585
Cancer Care and Hematology Specialists of Chicagoland
Winfield, Illinois, United States, 60190
Yorkville Family Practice
Yorkville, Illinois, United States, 60560
United States, Indiana
Cancer Care of Southern Indiana
Bloomington, Indiana, United States, 47403
Corydon Hospital Medical Plaza
Corydon, Indiana, United States, 47112
Michiana Hematology-Oncology, P.C. (Elkhart)
Elkhart, Indiana, United States, 46514
Elkhart Clinic
Elkhart, Indiana, United States, 46514
Waverly Hematology Oncology
Gary, Indiana, United States, 27518
Clark Medical Building
Jeffersonville, Indiana, United States, 47130
Howard Regional Health System
Kokomo, Indiana, United States, 46904
Michiana Hematology-Oncology, P.C. (LaPorte)
LaPorte, Indiana, United States, 46350
Cancer Care Center
New Albany, Indiana, United States, 47150
Michiana Hematology-Oncology PC
Plymouth, Indiana, United States, 46563
Oncology, P.C. Plymouth
Plymouth, Indiana, United States, 46563
Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States, 46601
Michiana Hematology-Oncology, P.C. Cedar St.
South Bend, Indiana, United States, 46617
Michiana Hematology-Oncology, P.C. (Main Office)
South Bend, Indiana, United States, 46601
South Bend Clinic
South Bend, Indiana, United States, 46117
Providence Medical Group
Terre Haute, Indiana, United States, 47802
United States, Iowa
Hematology and Medical Oncology Consultants-Bettendorf
Bettendorf, Iowa, United States, 52722
Hematology and Medical Oncology Consultants-Davenport
Davenport, Iowa, United States, 52804
University of Iowa
Iowa City, Iowa, United States, 52242
United States, Kansas
Lawrence Memorial Hospital
Lawrence, Kansas, United States, 66044
United States, Kentucky
University of Kentucky Medical Center
Lexington, Kentucky, United States, 40536
Norton Medical Plaza II
Louisville, Kentucky, United States, 40207
Norton Medical Plaza West
Louisville, Kentucky, United States, 40217
NortonHealthcare Pavillion
Louisville, Kentucky, United States, 40202
Old Brownsboro Crossing
Louisville, Kentucky, United States, 40241
United States, Louisiana
Baton Rouge General Medical Center
Baton Rouge, Louisiana, United States, 70806
United States, Maine
Eastern Maine Medical Center
Bangor, Maine, United States, 04401
United States, Maryland
Mercy Medical Center
Baltimore, Maryland, United States, 21202
Hematology-Oncology Associates
Baltimore, Maryland, United States, 21237
Harry & Jeannette Weinberg Cancer Institute
Baltimore, Maryland, United States, 21237
Franklin Square Hospital Center
Baltimore, Maryland, United States, 21237
Greater Baltimore Medical Center
Baltimore, Maryland, United States, 21204
Carolyn Hendricks, MD
Bethesda, Maryland, United States, 20817
Suburban Hospital
Bethesda, Maryland, United States, 20817
Washington Oncology-Hematology Center, PC-Chevy Chase
Chevy Chase, Maryland, United States, 20815
The Office of Frederik Smith
Chevy Chase, Maryland, United States, 20815
Associates in Oncology/Hematology
Rockville, Maryland, United States, 20850
Peninsula Regional Oncology & Hematology
Salisbury, Maryland, United States, 20817
Peninsula Regional Medical Center
Salisbury, Maryland, United States, 21801
Holy Cross Hospital
Silver Spring, Maryland, United States, 20910
Oncology Care Associates
Wheaton, Maryland, United States, 20902
United States, Massachusetts
Berkshire Hematology Oncology, P.C.-North Adams
North Adams, Massachusetts, United States, 01247
Berkshire Hematology Oncology, P.C.
Pittsfield, Massachusetts, United States, 01201
United States, Michigan
Bixby Medical Center
Adrian, Michigan, United States, 49221
CCOP, St. Joseph Mercy Hospital
Ann Arbor, Michigan, United States, 48106
Battle Creek Health System
Battle Creek, Michigan, United States, 49016
Dr. Cook and Abramson - Bay City
Bay City, Michigan, United States, 48706
Bay Regional Medical Center
Bay City, Michigan, United States, 48706
St. Joseph Mercy Woodland Health Center
Brighton, Michigan, United States, 48114
Josephone Ford Cancer Center
Brownstown, Michigan, United States, 48183
Henry Ford Medical Center-Fairlane
Dearborn, Michigan, United States, 48126
Henry Ford Hospital
Detroit, Michigan, United States, 48202
UP Hematology/Oncology Assoc.-Doctor's Park Family Physicians
Escanaba, Michigan, United States, 49829
Genesys Hurley
Flint, Michigan, United States, 48503
CCOP Hurley Medical Center
Flint, Michigan, United States, 48503
Sing and Arora
Flint, Michigan, United States, 48532
Genesys Regional Medical Center
Grand Blanc, Michigan, United States, 48439
St. Mary's Health Services
Grand Rapids, Michigan, United States, 49503
Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, United States, 49503
Spectrum Health Hospitals
Grand Rapids, Michigan, United States, 49503
CCOP, St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, United States, 19229
Portage Internal Medical Associates
Hancock, Michigan, United States, 49935
UP Hematology/Oncology Associates
Iron Mountain, Michigan, United States, 49801
UP Hematology/Oncology Associates-Gogebic Range
Ironwood, Michigan, United States, 49938
West Michigan Cancer Center
Kalamazoo, Michigan, United States, 49007
Hematology/Oncology Associates of OH and MI, PC
Lambertville, Michigan, United States, 48144
Michigan State University - Breslin Cancer Center
Lansing, Michigan, United States, 48910
CCOP, Sparrow Health System
Lansing, Michigan, United States, 48909
Lapeer Regional Hospital
Lapeer, Michigan, United States, 48446
Hematology Oncology-Lapeer
Lapeer, Michigan, United States, 48446
Keewanaw Memorial Hospital
Laurium, Michigan, United States, 49913
St. Mary Mercy Hospital - Livonia
Livonia, Michigan, United States, 48154
Upper Peninsula Hematology/Oncology Associates
Marquette, Michigan, United States, 49855
Marquette General Hospital
Marquette, Michigan, United States, 49855
Community Cancer Care Specialists-Mt. Clemens
Mt. Clemens, Michigan, United States, 48043
Mount Clemens Regional Medical Center
Mt. Clemens, Michigan, United States, 48043
Hackley Hospital
Muskegon, Michigan, United States, 49443
Michiana Hematology-Oncology PC
Niles, Michigan, United States, 49120
CCOP, William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
CCOP, St. Mary's Medical Center
Saginaw, Michigan, United States, 48601
Chippewa Medical Associates
Sault Saint Marie, Michigan, United States, 49783
Osteopathic Medical Oncology Hematology
Shelby Township, Michigan, United States, 48315
Lakeside Cancer Specialists, PLLC
St. Joseph, Michigan, United States, 49085
Michiana Hematology-Oncology, PC Lakeland
St. Joseph, Michigan, United States, 49085
Munson Medical Center
Traverse City, Michigan, United States, 49684
CCOP, St. John Macomb Hospital
Warren, Michigan, United States, 48093
Henry Ford Medical Center-West Bloomfield
West Bloomfield, Michigan, United States, 48322
Metro Health Hospital
Wyoming, Michigan, United States, 49519
United States, Minnesota
Park Nicollet Clinic
Burnsville, Minnesota, United States, 55337
Minnesota Oncology Hematology-Burnsville
Burnsville, Minnesota, United States, 55337
Hubert H. Humphrey Cancer Center - Coon Rapids
Coon Rapids, Minnesota, United States, 55433
Minnesota Oncology Hematology-Edina
Edina, Minnesota, United States, 55435
Fairview Southdale Medical Oncology Clinic
Edina, Minnesota, United States, 55455
Hubert H. Humphrey Cancer Center - Fridley
Fridley, Minnesota, United States, 55432
Minnesota Oncology Hematology PA - Maplewood
Maplewood, Minnesota, United States, 55109
Minnesota Oncology Hematology-Minneapolis
Minneapolis, Minnesota, United States, 55407
Hubert H. Humphrey Cancer Center-Robbinsdale
Robbinsdale, Minnesota, United States, 55422
Park Nicollet Health Services
St. Louis Park, Minnesota, United States, 55416
Minnesota Hematology Oncology-St. Paul
St. Paul, Minnesota, United States, 55102
Minnesota Oncology Hematology-Waconia
Waconia, Minnesota, United States, 55387
Minnesota Oncology Hematology
Woodbury, Minnesota, United States, 55125
United States, Mississippi
University of Tennessee Cancer Institute
Southaven, Mississippi, United States, 38671
United States, Missouri
University of Missouri-Ellis Fischel
Columbia, Missouri, United States, 65203
St. John's Regional Health Center-Joplin
Joplin, Missouri, United States, 64804
Freeman Cancer Institute
Joplin, Missouri, United States, 64804
Saint Luke's Hospital
Kansas City, Missouri, United States, 64111
CCOP, Kansas City (Administrative Only)
Kansas City, Missouri, United States, 64131
Cox Health Systems
Springfield, Missouri, United States, 65807
St. John's Regional Health Center
Springfield, Missouri, United States, 65805
United States, Montana
Hematology Oncology Centers of the Northern Rockies
Billings, Montana, United States, 59101
United States, Nevada
Comprehensive Cancer Centers of Nevada (Siena)
Henderson, Nevada, United States, 89052
Cancer Consultants
Las Vegas, Nevada, United States, 89106
Nevada Cancer Institute
Las Vegas, Nevada, United States, 89135
University Medical Center of Southern Nevada
Las Vegas, Nevada, United States, 89102
Cancer and Blood Specialists- Shadow Lane
Las Vegas, Nevada, United States, 89106
Renown Regional Medical Center
Reno, Nevada, United States, 89502
Alpine Hematology-Oncology
Reno, Nevada, United States, 89503
United States, New Jersey
Summit Medical Group
Berkeley Heights, New Jersey, United States, 07922
Drs. Forte, Schleider, Attas and Condemi, PA
Englewood, New Jersey, United States, 07631
Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, United States, 08690
Monmouth Medical Center
Long Branch, New Jersey, United States, 07740
Morristown Memorial Hospital
Morristown, New Jersey, United States, 07960
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901
Newark Beth Israel Medical Center
Newark, New Jersey, United States, 07112
University of Medicine and Dentistry of New Jersey
Newark, New Jersey, United States, 07103-2425
Sparta Cancer Treatment Center
Sparta, New Jersey, United States, 07871
Overlook Hospital
Summit, New Jersey, United States, 07901
United States, New York
NY Oncology Hematology PC at Albany Medical Center
Albany, New York, United States, 12208
New York Oncology Hematology PC-Albany
Albany, New York, United States, 12206
Amsterdam Community Cancer Program
Amsterdam, New York, United States, 12010
Interlakes Oncology & Hematology, P.C.
Canandaigua, New York, United States, 14424
Hematology Oncology Assaociates of CNY, CCOP
East Syracuse, New York, United States, 12010
NY Oncology Hematology PC-Hudson Carvell Cancer Tx Prog.
Hudson, New York, United States, 12534
NY Oncology Hematology PC- Latham- Capital District Oncology Hematology
Latham, New York, United States, 12110
Beth Israel Medical Center
New York, New York, United States, 10003
St. Luke's-Roosevelt Hospital Center
New York, New York, United States, 10019
Riverview Cancer Care Medical Association
Rexford, New York, United States, 12148
Hematology Oncology Associates of CNY, CCOP
Rome, New York, United States, 13440
University Hospital and Medical Center-SUNY
Stony Brook, New York, United States, 11794
University Hospital and Medical Center - SUNY
Stonybrook, New York, United States, 11794
Hematology Oncology Assoc. of CNY, CCOP (Comm. General Hospital Satellite Office)
Syracuse, New York, United States, 13215
Troy Cancer Treatment Program
Troy, New York, United States, 12180
United States, North Carolina
CCOP, Mission Hospitals, Inc.
Asheville, North Carolina, United States, 28801
Cancer Care of Western North Carolina
Asheville, North Carolina, United States, 28801
Cancer Center of NC at Asheville
Asheville, North Carolina, United States, 28803
Carolinas Hematology-Oncology - John J. Delaney
Charlotte, North Carolina, United States, 28277
Carolinas Medical Center - Blumenthal Cancer Center
Charlotte, North Carolina, United States, 28204
Carolinas Hematology Oncology Associates - Harris Blvd.
Charlotte, North Carolina, United States, 28262
Mecklenburg Medical Group - Morehead Medical Dr
Charlotte, North Carolina, United States, 28204
CCOP Presbyterian Hospital
Charlotte, North Carolina, United States, 28204
Mecklenburg Medical Group - Cameron Valley Pkwy
Charlotte, North Carolina, United States, 28211
Carolinas Hematology-Oncology Associates - Tyron St
Charlotte, North Carolina, United States, 28203
CCOP, Wayne Memorial Hospital
Goldsboro, North Carolina, United States, 27534
Moses Cone Regional Cancer Center
Greensboro, North Carolina, United States, 27403
Northwestern Carolina Oncology & Hematology, PA
Hickory, North Carolina, United States, 28603
Carolina BioOncology Institute
Huntersville, North Carolina, United States, 28078
United States, Ohio
Akron City Hospital
Akron, Ohio, United States, 44304
Akron General Medical Center
Akron, Ohio, United States, 44307
Alliance Cancer Center
Alliance, Ohio, United States, 44601
Aultman Hospital
Canton, Ohio, United States, 44710
Tri County Hematology/Oncology
Canton, Ohio, United States, 44781
Oncology/Hematology Care Clinical Trials LLC
Cincinnati, Ohio, United States, 45236
Oncology/Hematology Care Clinical Trials LLC, Cincinnati, OH Blue Ash Med. Cntr. (Administrative Only)
Cincinnati, Ohio, United States, 45242
North Treatment Center - Blue Ash Medical Center
Cincinnati, Ohio, United States, 45242
Oncology/Hematology Care Clinical Trials LLC
Cincinnati, Ohio, United States, 45242
Kenwood Office
Cincinnati, Ohio, United States, 45236
Case Western Reserve/University Hospitals-Ireland Cancer Cntr.
Cleveland, Ohio, United States, 44106
Dayton Physicians-LLC-Hematology & Medical Oncology Division
Dayton, Ohio, United States, 45415
Healthplex
Fairfield, Ohio, United States, 45014
Dayton Physicians, LLC - Greenville
Greenville, Ohio, United States, 45331
Hamilton Office
Hamilton, Ohio, United States, 45013
Marian A. Llenado Lee, MD, Inc.
Kettering, Ohio, United States, 45429
Dayton Clinical Oncology Program-Kettering
Kettering, Ohio, United States, 45429
Northwest Ohio Oncology Center
Maumee, Ohio, United States, 43537
UHHS - Chagrin Highlands
Orange Village, Ohio, United States, 44122
UHHS Green Road-Ireland Cancer Center
South Euclid, Ohio, United States, 44121
Flower Memorial Hospital
Sylvania, Ohio, United States, 43560
Toledo Clinic
Toledo, Ohio, United States, 43617
Bayview Oncology Associates
Toledo, Ohio, United States, 43616
UHHS Westlake-Ireland Cancer Center
Westlake, Ohio, United States, 44145
United States, Oregon
Northwest Cancer Specialists-Portland
Portland, Oregon, United States, 97213
Northwest Cancer Specialists-Adventist Office
Portland, Oregon, United States, 97216
Providence Oncology and Hematology Care Clinic
Portland, Oregon, United States, 97225
Adventist Medical Center
Portland, Oregon, United States, 97216
CCOP, Columbia River Oncology
Portland, Oregon, United States, 97225
Providence St. Vincent Medical Center
Portland, Oregon, United States, 97225
Providence Portland Medical Center
Portland, Oregon, United States, 97213
United States, Pennsylvania
Lehigh Valley Hospital
Allentown, Pennsylvania, United States, 18105
Geisinger Clinic
Danville, Pennsylvania, United States, 17882-2170
Hematology Oncology Associates of NE PA
Donora, Pennsylvania, United States, 18142
Ephrata Cancer Center at Ephrata Community Hospital
Ephrata, Pennsylvania, United States, 17522
UPMC Cancer Centers Arnold Palmer Pavilion-Mountainview
Greensburg, Pennsylvania, United States, 15601
UPMC Cancer Centers Arnold Palmer-Oakbrook
Greensburg, Pennsylvania, United States, 15601
UPMC Cancer Centers-Indiana
Indiana, Pennsylvania, United States, 15701
UPMC Cancer Centers-John P. Murtha Cancer Center
Johnstown, Pennsylvania, United States, 15901
UPMC Cancer Centers - McKeesport Hospital
McKeesport, Pennsylvania, United States, 15132
Riddle Memorial Hospital
Media, Pennsylvania, United States, 19063
UPMC Cancer Centers Arnold Palmer-Mt. Pleasant
Mt. Pleasant, Pennsylvania, United States, 15666
Kimmel Cancer Center at Jefferson
Philadelphia, Pennsylvania, United States, 19107
Albert Einstein Healthcare Network
Philadelphia, Pennsylvania, United States, 19141-3098
Cancer Center at Center One
Philadelphia, Pennsylvania, United States, 19115
UPMC Cancer Centers - UPMC Passavant
PIttsburgh, Pennsylvania, United States, 15237
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Hillman Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
UPMC Cancer Centers - UPMC St. Margaret
Pittsburgh, Pennsylvania, United States, 15215
Allegheny General Hospital/Allegheny-Singer Research Institute
Pittsburgh, Pennsylvania, United States, 15212
NSABP Foundation, Inc
Pittsburgh, Pennsylvania, United States, 15212
Scranton Hematology Oncology
Scranton, Pennsylvania, United States, 18501
Hematology and Oncology Associates
Scranton, Pennsylvania, United States, 18510
Mercy Hospital
Scranton, Pennsylvania, United States, 18501
Mount Nittany Medical Center
State College, Pennsylvania, United States, 16803
UPMC Cancer Centers-Uniontown
Uniontown, Pennsylvania, United States, 15401
UPMC Cancer Centers - Wexford
Wexford, Pennsylvania, United States, 15090
York Hospital
York, Pennsylvania, United States, 17403
United States, Tennessee
Thompson Oncology Group-Blount
Knoxville, Tennessee, United States, 37804
Thompson Oncology Group-West
Knoxville, Tennessee, United States, 37932
Thompson Cancer Survival Center-Dowell Springs
Knoxville, Tennessee, United States, 37909
Thompson Cancer Survival Center
Knoxville, Tennessee, United States, 37916
The West Clinic
Memphis, Tennessee, United States, 38120
United States, Texas
Texas Oncology- Sammons CC
Dallas, Texas, United States, 75246
The Center for Cancer and Blood Disorders
Fort Worth, Texas, United States, 76104
Ben Taub General Hospital
Houston, Texas, United States, 77030
Baylor College of Medicine
Houston, Texas, United States, 77030
Covenant Health System dba Joe Arrington Cancer Research & Treatment Center
Lubbock, Texas, United States, 79410
North Texas Regional Cancer Center
Plano, Texas, United States, 75075
United States, Utah
Intermountain Medical Center
Murray, Utah, United States, 84107
McKay-Dee Hospital
Ogden, Utah, United States, 84403
Utah Valley Regional Medical Center
Provo, Utah, United States, 84604
LDS Hospital
Salt Lake City, Utah, United States, 84143
Dixie Medical Center
St. George, Utah, United States, 84780
United States, Virginia
MBCCOP, Virginia Commonwealth University
Richmond, Virginia, United States, 23298
VCU Massey Cancer Center at Stony Point
Richmond, Virginia, United States, 23235
United States, Washington
Overlake Internal Medicine
Bellevue, Washington, United States, 98004
Rockwood Cancer Treatment Center - Sinto Ave
Spokane, Washington, United States, 99204
Rockwood Cancer Treatment Center
Spokane, Washington, United States, 99204
Northwest Cancer Specialists-134th St.
Vancouver, Washington, United States, 98686
Southwest Washington Hospital
Vancouver, Washington, United States, 98664
Northwest Cancer Specialists-136th Ave
Vancouver, Washington, United States, 98684
United States, West Virginia
West Virginia University Hospitals Inc.
Morgantown, West Virginia, United States, 26506-9162
United States, Wisconsin
Oncology Alliance-Burlington
Burlington, Wisconsin, United States, 53105
Oncology Alliance-Franklin
Franklin, Wisconsin, United States, 53132
Oncology Alliance
Glendale, Wisconsin, United States, 53212
Aurora BayCare Medical Center
Green Bay, Wisconsin, United States, 54311
Oncology Alliance-Kenosha South
Kenosha, Wisconsin, United States, 53143
Oncology Alliance-Kenosha North
Kenosha, Wisconsin, United States, 53144
CCOP, Marshfield Clinic
Marshfield, Wisconsin, United States, 54449
Oncology Alliance-Menomonee Falls
Menomonee Falls, Wisconsin, United States, 53051
Oncology Alliance-Mequon
Mequon, Wisconsin, United States, 53092
Oncology Alliance-South
Milwaukee, Wisconsin, United States, 53215
Oncology Alliance-Racine
Racine, Wisconsin, United States, 53406
Oncology Alliance-Waukeska
Waukesha, Wisconsin, United States, 53188
Marshfield Clinic Weston Center
Weston, Wisconsin, United States, 54476
Argentina
Hospital Universitario Austral
Derqui, Buenos Aires, Argentina, B1629ODT
Breast Clinica de la mama
La Plata, Buenos Aires, Argentina, B1902CMV
Centro Oncologico Rosario (COR)
Rosario, Sante Fe, Argentina, S2000DSK
Hospital Britanico de Buenos Aires
Buenos Aires, Argentina, C1280AEB
CEMIC
Buenos Aires, Argentina, C1431FWO
Australia, New South Wales
Macarthur Cancer Center
Campbelltown, New South Wales, Australia, 2560
St. George Hospital
Kogarah, New South Wales, Australia, 2217
Cancer Therapy Center
Liverpool, New South Wales, Australia, 1871
Royal North Shore Hospital
St. Leonards, New South Wales, Australia, 2065
North Shore Private Hospital
St. Leonards, New South Wales, Australia, 2065
Southern Medical Day Care
Wollongong, New South Wales, Australia, 2500
Australia, Queensland
Royal Brisbane & Women's Hospital
Herston, Queensland, Australia, 4029
Mater Adult Hospital
South Brisbane, Queensland, Australia, 4101
Australia, South Australia
Ashford Cancer Center
Ashford, South Australia, Australia, 5035
Flinders Medical Centre
Bedford, South Australia, Australia, 5042
Australia, Victoria
Frankston Hospital
Frankston, Victoria, Australia, 3199
The Alfred Hospital
Melbourne, Victoria, Australia, 3004
Australia, Western Australia
Mount Medical Center
Perth, Western Australia, Australia, 6000
Berdat Family Comprehensive Cancer Centre
Subiaco, Western Australia, Australia, 6008
Austria
Medizinische Universitat Graz - Onkologie
Graz, Austria, A-8036
Universitatsfrauenklinik Graz
Graz, Austria, 8036
Krankenhaus Barmherzige Brueder Graz, Medizinische Abteilung
Graz, Austria, 8020
AI University Hospital Innsbruck
Innsbruck, Austria, A-6020
Bezirkskrankenhaus Kufstein, Innere Medizin
Kufstein, Austria, 6330
Landeskrankenhaus Leoben, Abteilung fur Haemato-Onkologie
Leoben, Austria, 8700
Krankenhaus Barmherzige Schwestern Linz, Kooperative Studiengruppe, Chirurgie
Linz, Austria, 4010
AI Universitätsklinikum der PMU Landeskliniken
Salzburg, Austria, 5020
AKH Vienna
Vienna, Austria, 1090
Medizinische Universitaet Wien-Allgemeines Krankenhaus, Onkologie
Vienna, Austria, 1090
Krankenhaus Hietzing, Gynaekologische Abteilung
Vienna, Austria, 1130
Landeskrankenhaus Voecklabruck, 2. Medizinische Abteilung
Voecklabruck, Austria, 4840
Klinikum Wels-Grieskirchen, Kooperative Gruppe Wels/4. Medizinische Abteilung
Wels, Austria, 4600
Belgium
AZ Klina
Brasschaat, Belgium, 2930
C. H. Notre-Dame and Reine Fabiola
Charleroi, Belgium, 6000
Clinique St Pierre
Ottignies, Belgium, 1340
Medical Institute St. Augustinus
Wilrijk, Belgium, 2610
Bosnia and Herzegovina
Clinical Centre University of Sarajevo
Sarajevo, Bosnia and Herzegovina, 71000
Brazil
Centro Goiano de oncologia
Goiania, GO, Brazil, 74075-040
Lifecenter Sistema de Saude S/A
Belo Horizonte, MG, Brazil, 30110-090
Clinica Oncologistas Associados
Rio de Janeiro, RJ, Brazil, 22260-020
Instituto Nacional de Cancer
Rio de Janeiro, RJ, Brazil, 20560-120
Assoiacao hospital de caridade de ijui
Ijui, RS, Brazil, 98700-000
Hospital Das Clinicas de Porto Alegre-HCPA
Porto Alegre, RS, Brazil, 90035-003
Irmandade da Santa Casa de Misericoria de Porto Alegre Nucleo de Novos Tratamentos
Porto Alegre, RS, Brazil, 90050-170
Clinica de Oncologia de Porto Alegre
Porto Alegre, RS, Brazil, 90430-090
Fundacao Dr. Amaral Carvalho
Jau, SP, Brazil, 17210-080
Instituto de Oncologia Clinica de Piracicaba
Piracicaba, SP, Brazil, 13419-155
Centro de Oncologia e Hematologia da Faculdade de Medicina do ABC
Santo Andre, SP, Brazil, 09060-650
Instituto do Cancer de Sao Paulo
Sao Paulo, SP, Brazil, 01246-000
Conjunto Hospitalar de Sorocaba
Sorocaba, Brazil, 18030-075
Bulgaria
District Oncology Dispensary Plovdiv
Plovdiv, Bulgaria, 4000
MHAT "Tsaritsa Yoanna-ISUL" EOOD
Sofia, Bulgaria, 1527
Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2
Cross Cancer Institute, Dept of Medicine
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Lion's Gate Hospital
North Vancouver, British Columbia, Canada, V7L 2L7
Canada, Newfoundland and Labrador
Dr. H. Bliss Murphy Cancer Centre
St. Johns, Newfoundland and Labrador, Canada, AIB 3V6
Canada, Ontario
William Osler Health Center
Brampton, Ontario, Canada, L6R 3J7
Credit Valley Hospital
Mississauga, Ontario, Canada, L5M 2N1
Southlake Regional Health Centre
New Market, Ontario, Canada, L3Y 2P9
Ottawa Hospital Regional Cancer Centre
Ottawa, Ontario, Canada, K1H 8L6
St. Michaels Hospital
Toronto, Ontario, Canada, M5B 1W8
Humber River Regional Hospital
Weston, Ontario, Canada, M9N 1N8
Windsor Regional Cancer Centre
Windsor, Ontario, Canada, N8W 2X3
Canada, Quebec
Hopital Charles LeMoyne
Greenfield Park, Quebec, Canada, J4V 2H1
Hopital Maisonneuve Rosemont
Montreal, Quebec, Canada, H1T 2M4
University of Montreal Hospital Group
Montreal, Quebec, Canada
Montreal General Hospital
Montreal, Quebec, Canada, H3G 1A4
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Royal Victoria Hospital
Montreal, Quebec, Canada, H3A 1A1
Hospital du Sacre-Coeur
Montreal, Quebec, Canada, H4J 1C5
Centre Hospitalier Affilie Universitaire De Quebec, Hospital du St-Sacrement
Quebec City, Quebec, Canada, G1S 4L8
Chile
Hospital Regional Rancagua
Rancagua, VI Region, Chile, 2820000
China
The Pla 307 Hospital
Beijing, China, 100071
Chinese Academy of Medical Science
Beijing, China, 100021
Chinese PLA General Hospital
Beijing, China, 100853
Jilin Cancer Hospital
Changchun, China, 130012
West China Hospital, Sichuan University
Chengdu, China, 610041
Fuzhou General Hospital of Nanjing Military Area
Fuzhou, China, 354200
Sun Yat-sen University Hospital
Guangzhou, China, 510060
Zhejiang Tumor Hospital
Hangzhou, China, 310022
1st Affiliated Hospital of Zhejiang University
Hangzhou, China, 310003
Tianjin Cancer Hospital
Tianjin, China, 300060
Croatia
University Hospital Zagreb
Zagreb, Croatia, 10000
Czech Republic
FN Na Bulovce
Praha 8, Czech Republic, 180 81
Egypt
National Cancer Institute
Cairo, Egypt, 11796
Estonia
Tartu University Hospital Clinic of Hematology and Oncology
Tartu, Estonia, 51014
France
CHU D'Amiens
Amiens, France, 80054
CH-Service Hemato-Oncologie
Beauvais, France, 60000
Clinique Bordeaux Nord Aquitaine
Bordeaux, France, 33300
CHU Morvan
Brest, France, 29609
Hopital Pasteur
Colmar, France, 68024
Ch intercommunal de creteil
Creteil, France, 94000
Centre Leonard de Vinci
Dechy, France, 59187
Institut Daniel Hollard
Grenoble, France, 38028
CHD les Oudairies
La Roche sur Yon Cedex, France, 85925
Clinique Francois Chenieux
Limoges, France, 87039
CHU Dupuytren
Limoges, France, 87042
Hopital St. Joseph
Marseille, France, 13008
Centre Regional de Lutte contre le Cancer (CRLC) Val d'Aurelle
Montpellier, France, 34298
Centre Catherine de Sienne
Nantes Cedex, France, 44202
Clinique Hartmann
Neuilly sur Seine, France, 92200
CHU Hotel Dieu
Paris, France, 75004
Hopital St. Antoine
Paris Cedex 12, France, 75571
Clinique Saint Hilaire
Rouen, France, 76000
CLCC Paul Strauss
Strasbourg, France, 67085
Pole de cancerologie prive
Strasbourg, France, 67000
Polyclinique du Parc
Toulous, France, 31400
Institution Claudius Regaud
Toulouse Cedex, France, 31052
Germany
Klinikum St. Marien Amberg
Amberg, Germany, 92224
Hochwaldkrankenhaus
Bad Nauheim, Germany, 61231
Klinikverbund Suedwest - Sindelfingen-Böeblingen Clinical Centre
Böeblingen, Germany, 71032
Klinikum Chemnitz
Chemnitz, Germany, 09116
Universitaetsklinikum Dresden
Dresden, Germany, 01307
Luisenkrankenhaus
Duesseldorf, Germany, 40235
Universitaetsfrauenklinik
Essen, Germany, 45122
Zentrum fur Frauenheilkunde und Geburtshilfe
Frankfurt, Germany, D-60590
Medizinisches Versorgungszentrum Osthessen
Fulda, Germany, 36043
Kreiskrankenhaus Hameln
Hameln, Germany, 31785
Klinikum Stadt Hanau
Hanau, Germany, 63450
Klinikum Hannover Nordstadt
Hannover, Germany, 30167
Universitat Frauenklinik Jena
Jena, Germany, 07743
Onkologische schwerpunktpraxis
Leer, Germany, 26789
Klinikum Lippe Lemgo
Lemgo, Germany, D-32657
Asklepios Kliniken Lich GmbH
Lich, Germany, 35423
St. Vincenz u. Elisabeth Hospital
Mainz, Germany, 55131
Universitaetsklinikum Mainz
Mainz, Germany, 55101
RotKreuzKlinikum München GmbH
Munich, Germany, 80637
Universitaetsklinikum Munster
Munster, Germany, 48129
Ev Krankenhaus Bethesda
Mönchengladbach, Germany, 41061
Praxis und Tagesklinik fuer Onkologie und
Recklinghausen, Germany, 45657
Klinikum Rosenheim
Rosenheim, Germany, 83022
Klinikum Schaumburg
Stadhagen, Germany, 31655
Johanniter Krankenhaus
Stendal, Germany, D-39576
Robert-Bosch-Krankenhaus
Stuttgart, Germany, 70376
Fachärzte fürlnnere Medizin, Hämatologie
Traunstein, Germany, 83278
Greece
P.G. Hospital of Thessaloniki "Papageorgiou"
Thessaloniki, Greece, 56429
Hong Kong
Queen Elizabeth Hospital
Hong Kong, Hong Kong
Prince of Wales Hospital
Hong Kong, Hong Kong
Hungary
Semmelweis Egyetem Clinic of Radiology
Budapest, Hungary, 1082
DEOEC Onkologiai Tanszek
Debrecen, Hungary, 4012
Petz Aladar Megyei Oktato
Gyor, Hungary
Kaposi Mor oktato korhaz Onkologiai tanszek
Kaposvar, Hungary, H-7400
Ireland
Cork University Hospital
Cork, Ireland
Mater Private Hospital
Dublin, Ireland
Beaumont Hospital
Dublin, Ireland, 0009
Adelaide and Meath National Childrens Hospital
Dublin, Ireland
St. James's Hospital
Dublin, Ireland, 8
Institute for Cancer Research
Dublin, Ireland
St. Vincent's University Hospital
Dublin 4, Ireland
University College Hospital Galway
Galway, Ireland
Midwestern Regional Hospital
Limerick, Ireland
Sligo General Hospital
Sligo, Ireland
Israel
The Lady Davis Carmel Medical Center/Lynn
Haifa, Israel
Meir Medical Center
Kfar, Israel, 13100
Kaplan Medical Center
Rehovot, Israel
Sourasky (Ichilov) Medical Center
Tel Aviv, Israel
Ziv Medical Center
Zefat, Israel
Assaf Harofeh Medical Center
Zerifin, Israel
Italy
Humanitas Centro Catanese
Catania, Italy, 95126
(Azienda u.s.I. chieti) - Policinico Ospedaliero
Chieti, Italy, 66100
Ospedale vito fazzi
Lecce, Italy
Ospedale di Mirano
Mirano, Italy
IRCCS - Instituto Nazionale per lo Studio e la Cura
Napoli, Italy, 80131
Fondazione Salvatore Maugeri
Pavia, Italy, 27100
Ospedale S. Filippo Neri
Roma, Italy, 00135
Regina Elena Cancer Institute
Rome, Italy
Ospedale casa sollievo della sofferenza
San-Giovanni, Italy
Universita-istituto Clinica Medica
Sassari, Italy, 07100
Asl n. 5 -Ospedale s. Vincenzo
Taormina, Italy
Korea, Republic of
Seoul National University Bundang Hospital
Gyeonggi-do, Korea, Republic of, 463-707
Asan Medical Center
Seoul, Korea, Republic of, 138-736
Samsung Medical Center
Seoul, Korea, Republic of, 135-710
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Severance Hospital
Seoul, Korea, Republic of, 120-752
Latvia
P. Stradina Clinical University Hospital
Riga, Latvia
Mexico
Opcion Oncologia
Monterrey, Mexico, 64060
Peru
Hospital Nacional Carlos Alberto Seguin
Arequipa, Peru
Hospital Nacional Edgardo Rebagliati Martins
Lima, Peru, Lima 11
Philippines
Cebu Doctors University Hospital
Cebu City, Philippines, 6000
Poland
Regional Oncology Center
Bialystok, Poland
Centrum Onkologii Instytut im. M.
Gliwice, Poland, 44-101
Olsztynski Osrodek Onkologiczny "Kopernik"
Olsztyn, Poland, 10-513
ZOZ MSWiA z Warminsko-Mazurskim Centrum
Olsztyn, Poland, 10-228
Samodzielny Publiczny Zaklad Opieki
Rybnik, Poland, 44-200
Breast Cancer Clinic
Warsaw, Poland, 02-781
Portugal
HUC
Coimbra, Portugal, 3000-073
IPO Francisco Gentil-Porto
Porto, Portugal, 4200-319
Romania
County Hospital Alba-Iulia
Alba-Iulia, Romania, 510000
Institute of Oncology "AI.Trestioreanu"
Bucharest, Romania, 022338
Institutul Oncologic "Prof. Dr. I. Chiricuta" Cluj-Napoca
Cluj-Napoca, Romania
Russian Federation
State Medical Institution "Republican Clinical Oncology Dispensary Ministry of Health of Republic Tatarstan"
Kazan, Russian Federation
State Institution "Russian Oncological Research Center n.a. N.N. Blokhin of RAMS"
Moscow, Russian Federation
Saint-Petersburg State Medical Institution "City Clinical Oncology Dispensary"
Saint Petersburg, Russian Federation
Federal State Institution "Research Institute of Oncology n.a. N.N. Petrov Rosmedtechnologiy"
Saint Petersburg, Russian Federation
Serbia
Clinical Hospital Center Bezanijska Kosa
Belgrade, Serbia, 11080
Clinic of Oncology, Clinical Center nis
Nis, Serbia, 18000
Slovenia
University Clinical Centre
Maribor, Slovenia, 2101
South Africa
Department of Oncotherapy National Hospital
Bloemfontein, South Africa, 9301
Hopelands Cancer Centre
Durban, South Africa, 4001
Johannesburg Hospital
Johannesburg, South Africa
Spain
Hospital Universitario Insular de Gran Canaria
Las Palmas, Canary Islands, Spain, 33106
Fundacion Hospitalaria de Alcorcon
Alcorcon, Spain, 28922
Hospital General de Alicante
Alicante, Spain, 03010
Hospital Perpetuo Socorro
Badajoz, Spain, 6010
Hospital Germans Trias l Pujol
Badalona (Barcelona), Spain, 08916
Hospital Comarcal de Barbastro
Barbastro, Spain, 22300
Hospital Espiritu Santo
Barcelona, Spain, 08923
Hospital Santa Crue l San Pau
Barcelona, Spain, 08025
Althaia Xarxa Assistencial de Manresa
Barcelona, Spain, 08243
Consorci Sanitari de Terrassa
Barcelona, Spain, 08227
Hospital Clinic i Provincial
Barcelona, Spain, 08036
Hospital Del Mar
Barcelona, Spain, 08003
Hospital De San Pedro de Alcantara
Caceres, Spain, 10003
Hospital Gral. De Elche
Elche, Spain, 03202
Hospital de Cabueñes, Oncologia Médica
Gijon, Spain, 33394
Instituto Catalan Oncologia de Girona
Girona, Spain, 17007
Complejo Hospitalario de Jaen
Jaen, Spain, 23007
Complejo Hospitalario Universitario A Coruna
La Coruna, Spain, 15006
Centro Oncologico de Galicia
La Coruña, Spain, 15009
Hospital Universitario de Canarias
La Laguna, Spain, 38320
Hospital Xera Calde
Lugo, Spain
Centro Integral de Oncologia "Clara Campal"
Madrid, Spain, 28050
Hospital Universitario San Carlos
Madrid, Spain, 28040
Hospital Universitario Gregorio Maranon
Madrid, Spain, 28007
Fundacion Jimenez Diaz
Madrid, Spain, 28040
Hospital Ruber International
Madrid, Spain, 28034
Hospital Clinico Virgen de la Victoria
Malaga, Spain, 29010
Hospital Univesitario Carlos Haya
Malaga, Spain, 29010
Hospital Santa Maria Nai Dr. Cabaleiro
Ourense, Spain
Complejo Hospitalario de Pontevedra
Pontevedra, Spain, 36001
Hospital del Parc Tauli
Sabadell, Spain, 08208
Hospital Universitario de Salamanca
Salamanca, Spain, 37007
Instituto Oncologico de Guipuzcoa
San Sebastian, Spain
Hospital Universitario Virgen del Rocio
Sevilla, Spain, 41013
Hospital Torrevieja Salud, UTE
Torrevieja, Spain, 03186
Hospital Clinico Universitario de Valencia
Valencia, Spain, 46010
Hospital U. Miguel Servet
Zaragoza, Spain, 50009
Hospital Clinico Universitario Lozano Blesa
Zaragoza, Spain, 50009
Sweden
Sahlgrenska University Hospital
Goteborg, Sweden, 41345
Karolinska University Hospital
Stockholm, Sweden, S-118
Taiwan
Changhua Christian Hospital
Changhua, Taiwan, 500
Kaohsiung Medical University Chung
Kaohsiung, Taiwan, 807
National Cheng Kung University
Tainan, Taiwan, 704
Sun Yat-Sen Cancer Center
Taipei, Taiwan, 112
Taipei Veterans General Hospital
Taipei, Taiwan, 112
Chang Gung Memorial Hospital
Taoyuan, Taiwan, 3330
Thailand
Chulalongkorn Hospital
Patumwan, Bangkok, Thailand, 10330
National Cancer Institute
Bangkok, Thailand, 10400
Songklanagarind Hospital
Songkhla, Thailand
United Kingdom
Royal Bournemouth Hospital
Bournemouth, United Kingdom, BH7 7DW
Bristol Hematology - Oncology Centre
Bristol, United Kingdom, BS2 8ED
Ipswich Hospital
Ipswich, United Kingdom, IP4 5PD
Christie Hospital NHS Trust
Manchester, United Kingdom, M20 4BX
Nottingham City Hospital
Nottingham, United Kingdom, NG5 1PB
Peterborough District Hospital
Peterborough, United Kingdom, PE3 6DA
Sunrise Cancer Centre
Truro, United Kingdom, TR1 3IJ
Sponsors and Collaborators
NSABP Foundation Inc
Cancer International Research Group
Hoffmann-La Roche
Genentech, Inc.
Investigators
Principal Investigator: Norman Wolmark, MD NSABP Foundation Inc
  More Information

No publications provided

Responsible Party: NSABP Foundation Inc
ClinicalTrials.gov Identifier: NCT00625898     History of Changes
Other Study ID Numbers: NSABP B-44-I, CIRG (TRIO) 011, Roche BO20906, BETH
Study First Received: February 21, 2008
Last Updated: July 7, 2014
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Canada: Ethics Review Committee

Keywords provided by NSABP Foundation Inc:
HER2 positive breast cancer
invasive breast cancer
bevacizumab
NSABP
Roche
CIRG
trastuzumab
cyclophosphamide
docetaxel
carboplatin
5-fluorouracil
epirubicin

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Bevacizumab
Carboplatin
Cyclophosphamide
Docetaxel
Epirubicin
Fluorouracil
Trastuzumab
Alkylating Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists

ClinicalTrials.gov processed this record on October 21, 2014